Search results for: France
Filter search results
Comparing Prescription Medicines Prices in the UK to Prices in Other Countries
23 October 2012
…Finland, France, Germany, Ireland, Italy, The Netherlands, Spain, Sweden and the US. To ensure the medicines included do match, various databases were used. The total sample of preparations included in…
Is It Time to Reconsider the Role of Co-Payments in Europe?
11 January 2012
…co-pays The Netherlands and Malta 2. Flat-rate Austria, Italy, UK (with implicit ceiling prescription pre-payment certificate) 3. Percentage rates Belgium, France, Greece, Estonia, Finland (with annual ceiling), Latvia, Lithuania, Poland,…
OHE in the Spotlight: Summer 2011
22 September 2011
…Towse chaired a session of experts from the UK, the US and France that focused primarily on the role VBP would have in aligning the incentives for investment in pharmaceutical…
The Spanish Medicines Market Today
9 February 2011
…half of the average of 2% for the five largest European markets. Reimbursement over the same period grew 2.3%, above Italy’s -1.2%, but well below France at 3.3%, the UK…
Access to Orphan Drugs in the EU
21 October 2010
…late September. The OHE study compares P&R policy for 43 OMPs across seven EU Member States: France, Germany, Italy, The Netherlands, Spain, Sweden and the UK. In particular, the study…
Patterns of European Diagnoses and Prescribing
1 January 1984
…major European countries – France, Federal Germany, Italy, Spain and the UK. The data source was the Medical Data Index (MDI, 1982 data) which is an international sample survey of…
Biosimilars’ Price Dynamic in Europe
30 June 2010
…seminar and summarises the remarks of Dr Matthias Liefner of Simon Kucher and Partners. In Europe, pricing of biosimilars already has begun to affect the market for biologics. For example, France’s compulsory…
European Medicines Pricing and Reimbursement: Now and the Future
1 January 2007
…scenarios that might emerge in the next decade. – Martina Garau and Jorge Mestre-Ferrandiz in the Introduction Contents – Pricing and reimbursement policies in France: current and future trends; Pricing…
Incentives, Competition, and Pharmaceutical Innovation in Europe: The Case of Direct Acting Antivirals for Hepatitis C
26 July 2018
…curves and market shares demonstrate that access to DAAs was sped up in this second stage for Germany, Spain, Italy and Portugal. For France, access was already high at this…